Published on 9 May 2024 on Benzinga via Yahoo Finance
Japan's Takeda Pharma Outlines $900M Overhaul To Boost Growth, As 2023 Profit Fall Over 50%
Japan's Takeda Pharma Outlines $900M Overhaul To Boost Growth, As 2023 Profit Fall Over 50%
On Thursday, Japan’s drugmaker Takeda Pharmaceutical Company Limited (NYSE:TAK) announced a restructuring after the company reported a fiscal year 2023 net profit of 144 billion yen (around $954 million), down 54.6% Y/Y.
Core net profit fell 12.6% (down 15% at constant currency) to 756.8 billion yen.